Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 7/20 | 0.48 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472239 | 0.86 | DPP4 (0.56) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL9437304 | 0.82 | TOP2A (0.58) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL5142702 | 0.82 | DPP4 (0.58) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL10330767 | 0.80 | TOP2A (0.59) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL10876232 | 0.80 | DPP4 (0.59) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL500472 | 0.80 | DPP4 (0.57) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL14143514 | 0.79 | DPP4 (0.54) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL10413901 | 0.79 | DPP4 (0.55) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL17537044 | 0.78 | DPP4 (0.56) | DPP4CHRM2DRD1TOP2ATOP2B | |
| SCHEMBL9279260 | 0.78 | DPP4 (0.55) | DPP4CHRM2DRD1TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991992-B1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9540399-B2 | Quinolone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-2991992-A1 | QUINOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060276-A1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-03 | — | — | US | disclosed |
| WO-2014178008-A1 | QUINOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060276-A1 | QUINOLONE DERIVATIVES | NQO2, QARS1, RECQL | DPP4 1991/4885CHRM2 1273/4885DRD1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.